RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionESMO 2022 - Poster - Results from Aware-1
https://oncolyticsbiotech.com/wp-content/uploads/2022/04/AWARE-1-ESMO-BC-poster.pdf
Conclusion:
Previously we showed that Cohort 2 met the study’s success criterion of ≥30% increase in CelTIL score in at least 50% of the patients
The additional translational research results presented here show that pelareorep and atezolizumab act synergistically to establish a favorable immunologic response in both the tumor and the blood as demonstrated by:
o Changes in the T cell populations including decreases in clonal T cell diversity, which is associated with increased CelTIL scores and TILs at surgery (Day 21)
o Upregulation of caspase 3 in tumor samples
o A favorable change from luminal B to luminal A subtype (better prognosis) and decrease in risk of recurrence (ROR)
o An increase in markers of T cell activation and no significant change in markers of T cell exhaustion
These data illustrate pela’s ability to induce an inflamed tumor phenotype and demonstrate its synergy with atezo. Moreover, they support pela’s immune-based mechanism of action and suggest that combining pela with atezo may improve outcomes in BC patients.
References [1] Samson et al. Sci Transl Med 2018;10. [2] Bernstein et al. Breast Cancer Res Treat (2018);167:485-93. [3] Nuciforo et al. Ann Oncol (2018), 29: 170-77. [4] Manso et al. AACR Virtual Annual Meeting (2021). Disclosures of J. Gavila : Astra-Zeneca, Pfizer, Novartis, Roche. Email: jogagre@hotmail.co